Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial

Olli P. O. Nevalainen, Saana Horstia, Sanna Laakkonen, Jarno Rutanen, Jussi M. J. Mustonen, Ilkka E. J. Kalliala, Hanna Ansakorpi, Hanna-Riikka Kreivi, Pauliina Kuutti, Juuso Paajanen, Seppo Parkkila, Erja-Leena Paukkeri, Markus Perola, Negar Pourjamal, Andreas Renner, Tuomas Rosberg, Taija Rutanen, Joni Savolainen, Jari K. Haukka, Gordon H. Guyatt and Kari A. O. Tikkinen ()
Additional contact information
Olli P. O. Nevalainen: University of Helsinki
Saana Horstia: University of Helsinki
Sanna Laakkonen: University of Helsinki
Jarno Rutanen: Tampere University
Jussi M. J. Mustonen: City of Helsinki
Ilkka E. J. Kalliala: Helsinki University and University Hospital Helsinki
Hanna Ansakorpi: University of Oulu
Hanna-Riikka Kreivi: University of Helsinki and Helsinki University Hospital
Pauliina Kuutti: University of Helsinki
Juuso Paajanen: University of Helsinki and Helsinki University Hospital
Seppo Parkkila: Tampere University and Fimlab Ltd., Tampere University Hospital
Erja-Leena Paukkeri: Tampere University Hospital
Markus Perola: Finnish Institute for Health and Welfare
Negar Pourjamal: University of Helsinki
Andreas Renner: University of Helsinki and Helsinki University Hospital
Tuomas Rosberg: Kanta-Häme Central Hospital
Taija Rutanen: Suomen Covid -yhdistys ry
Joni Savolainen: Suomen Covid -yhdistys ry
Jari K. Haukka: Tampere University
Gordon H. Guyatt: McMaster University
Kari A. O. Tikkinen: University of Helsinki and Helsinki University Hospital

Nature Communications, 2022, vol. 13, issue 1, 1-6

Abstract: Abstract We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-33825-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33825-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-33825-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().